Literature DB >> 27686093

Hepatic overexpression of cAMP-responsive element modulator α induces a regulatory T-cell response in a murine model of chronic liver disease.

Nadine Kuttkat1, Antje Mohs1, Kim Ohl2, Guido Hooiveld3, Thomas Longerich4, Klaus Tenbrock2, Francisco Javier Cubero1, Christian Trautwein1.   

Abstract

OBJECTIVE: Th17 cells are a subset of CD4+ T-helper cells characterised by interleukin 17 (IL-17) production, a cytokine that plays a crucial role in inflammation-associated diseases. The cyclic AMP-responsive element modulator-α (CREMα) is a central mediator of T-cell pathogenesis, which contributes to increased IL-17 expression in patients with autoimmune disorders. Since an increased Th17 response is associated with a poor prognosis in patients with chronic liver injury, we investigated the relevance of Th17 cells for chronic liver disease (CLD) and hepatocarcinogenesis.
DESIGN: Transgenic mice overexpressing CREMα were crossed with hepatocyte-specific Nemo knockout mice (NemoΔhepa) to generate NemoΔhepa/CREMαTg mice. The impact of CREMαTg on CLD progression was examined. Additionally, soft agar colony formation assays, in vitro studies, adoptive transfer of bone marrow-derived cells (BMDCs) and T cells, and gene arrays in T cells were performed.
RESULTS: 8-week-old NemoΔhepa/CREMαTg mice presented significantly decreased transaminase levels, concomitant with reduced numbers of CD11b+ dendritic cells and CD8+ T cells. CREMαTg overexpression in NemoΔhepa mice was associated with significantly reduced hepatic fibrogenesis and carcinogenesis at 52 weeks. Interestingly, hepatic stellate cell-derived retinoic acid induced a regulatory T-cell (Treg) phenotype in CREMαTg hepatic T cells. Moreover, simultaneous adoptive transfer of BMDCs and T cells from CREMαTg into NemoΔhepa mice ameliorated markers of liver injury and hepatitis.
CONCLUSIONS: Our results demonstrate that overexpression of CREMα in T cells changes the inflammatory milieu, attenuating initiation and progression of CLD. Unexpectedly, our study indicates that CREMα transgenic T cells shift chronic inflammation in NemoΔhepa livers towards a protective Treg response. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  CHRONIC LIVER DISEASE; HEPATOCELLULAR CARCINOMA; LIVER; NUCLEAR FACTOR KAPPA B; T LYMPHOCYTES

Mesh:

Substances:

Year:  2016        PMID: 27686093      PMCID: PMC5531221          DOI: 10.1136/gutjnl-2015-311119

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

Review 3.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 4.  IL-17 and Th17 Cells.

Authors:  Thomas Korn; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

5.  Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus.

Authors:  E E Solomou; Y T Juang; M F Gourley; G M Kammer; G C Tsokos
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

6.  Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury.

Authors:  Christian Liedtke; Jörg-Martin Bangen; Julia Freimuth; Naiara Beraza; Daniela Lambertz; Francisco J Cubero; Maximilian Hatting; Karlin R Karlmark; Konrad L Streetz; Gabriele A Krombach; Frank Tacke; Nikolaus Gassler; Dieter Riethmacher; Christian Trautwein
Journal:  Gastroenterology       Date:  2011-08-28       Impact factor: 22.682

Review 7.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

8.  CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice.

Authors:  Fangwei Liu; Jie Liu; Dong Weng; Ying Chen; Laiyu Song; Qincheng He; Jie Chen
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

9.  Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.

Authors:  Daniel Mucida; Yunji Park; Gisen Kim; Olga Turovskaya; Iain Scott; Mitchell Kronenberg; Hilde Cheroutre
Journal:  Science       Date:  2007-06-14       Impact factor: 47.728

10.  NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Authors:  Chi Ma; Aparna H Kesarwala; Tobias Eggert; José Medina-Echeverz; David E Kleiner; Ping Jin; David F Stroncek; Masaki Terabe; Veena Kapoor; Mei ElGindi; Miaojun Han; Angela M Thornton; Haibo Zhang; Michèle Egger; Ji Luo; Dean W Felsher; Daniel W McVicar; Achim Weber; Mathias Heikenwalder; Tim F Greten
Journal:  Nature       Date:  2016-03-02       Impact factor: 49.962

View more
  2 in total

1.  Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion.

Authors:  Yiming Liu; Xiaodi Zhang; Sining Zhou; Jieyao Shi; Yun Xu; Jia He; Feng Lin; Anbang Wei; Linfu Zhou; Zhi Chen
Journal:  J Cell Mol Med       Date:  2019-01-24       Impact factor: 5.310

Review 2.  Human Amnion Epithelial Cell Therapy for Chronic Liver Disease.

Authors:  Neil Andrewartha; George Yeoh
Journal:  Stem Cells Int       Date:  2019-08-07       Impact factor: 5.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.